NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 29, 2020

Study Completion Date

August 31, 2025

Conditions

Head and Neck CancerSquamous Cell CarcinomaOral Cavity CancerOropharynx CancerHypopharynx CancerLarynx CancerLaryngeal Cancer

Interventions

DRUG

pembrolizumab (MK-3475)

200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.

DRUG

Cisplatin

Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36

RADIATION

Radiation

70 Gy fractionated over 35 days

Trial Locations (4)

Sanford Health Cancer Center, Sioux Falls

Sanford-Roger Maris Cancer Center, Fargo

Sanford-Bismarck Medical Center, Bismarck

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sanford Health

OTHER